Exeliom Biosciences

Exeliom Biosciences is a clinical-stage biotechnology company leading the development of EXL01, a first-in-class immunomodulator designed to target NOD2 receptors in macrophages. By uniquely activating the NOD2 pathway, EXL01 drives metabolic reprogramming in monocytes and macrophages, unlocking powerful and precise immune-modulatory effects. Harnessing the versatility of this groundbreaking mechanism, EXL01 is currently in Phase 2 clinical trials across multiple therapeutic areas, including oncology (gastric, NSCLC, HCC, RCC), inflammatory bowel diseases (Crohn's disease), and infectious diseases (C. difficile infections). At Exeliom, we are transforming scientific innovation into transformative therapies.